Precipio Inc Stock Price, News & Analysis

Precipio (NASDAQ: PRPO) will host a Q3-2025 shareholder update conference call on November 17, 2025 at 5:00 PM ET. The call will cover updates on the company’s core businesses and allow investor questions submitted in advance via email to investors@precipiodx.com. Callers can access the live call by dialing 800.717.1738 and asking for the Precipio conference call. A replay will be available about 24 hours after the call on the Investors page at https://www.precipiodx.com/investors/.

Precipio (NASDAQ:PRPO), a specialty cancer diagnostics company, has announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners (AGP). The decision reflects the company's improved financial position, marked by the elimination of negative cash flow from operations and recent increases in cash balance.

CEO Ilan Danieli emphasized that the company is now stronger and no longer needs to rely on the ATM tool for capital raises, demonstrating management's commitment to enhancing shareholder value.

Precipio (NASDAQ: PRPO) reported strong Q2-2025 financial results, with total revenues reaching $5.7M, representing a 27% YoY increase and 15% QoQ growth. The company's Pathology Services division saw an 18% QoQ increase, while Product revenues grew 23% QoQ.

Key financial metrics show significant improvement with Adjusted EBITDA of ($78K), an 87% improvement YoY, and cash used in operations decreased 71% YoY to $148K. Overall gross margins improved from 39% to 43% YoY, despite a temporary decline in Product division margins from 50% to 44% due to strategic investments in expansion.

Management expects to achieve positive cash flow and a debt-free balance sheet by year-end, following the completion of the Change Healthcare loan repayment.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q2-2025 shareholder update conference call for August 14th, 2025 at 5:00 PM ET. The call will provide updates on the company's core business segments.

Shareholders can access the call by dialing 800.717.1738. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call through Precipio's investor relations website.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has restructured its warrant agreement with its largest warrant holder. Under the new agreement, 100,000 warrants will be exercised for cash, while the remaining 200,000 warrants will be exercised cashlessly.

The restructuring results in two key outcomes: 1) A reduction in share dilution, with total new shares decreasing from ~300,000 to ~130,000-150,000, and 2) A reduced cash inflow of $1.2 million instead of the original $3.8 million. Management will discuss this transaction during their upcoming quarterly shareholder call around August 15th, 2025.

Precipio (NASDAQ: PRPO) is urgently requesting shareholders to vote their shares by 11 PM ET on June 16, 2025, ahead of their Annual Shareholders Meeting scheduled for June 17, 2025. Currently, only 42% of shares have been voted, falling short of the 50% quorum requirement. The company warns that failing to reach quorum would force meeting adjournment, potentially incurring significant costs of up to $100,000 for rescheduling, compared to the current meeting cost of less than $5,000. These additional expenses would include hiring a proxy solicitor, legal fees, and administrative costs. Management emphasizes that shareholders can vote either for or against, but voting participation is crucial to avoid unnecessary expenditures.

Precipio (NASDAQ: PRPO) reported strong Q1-2025 financial results with revenues reaching $4.9M, a 43% YoY increase. The company saw significant improvements in key metrics: - Adjusted EBITDA improved 92% YoY to ($108K) - Cash used in operations improved 93% YoY to ($44K) - Overall gross margins increased from 27% to 43% YoY - Operating expenses dropped from 87% to 61% of net revenue The Pathology Services division grew 54% YoY with 46% increase in test volume, while the Products division successfully onboarded new customers and launched new panels. The company expects to return to positive cash flow by Q2/Q3 2025, supported by a $400K non-recurring income from CARES Act and MolDx approval for NGS testing enabling Medicare billing.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q1-2025 shareholder update conference call for May 15th, 2025 at 5:00 PM ET. The call will provide updates on all of the company's core businesses.

Shareholders can access the call by dialing 844-695-5519 (international: 1-412-902-6760) or pre-register at the provided link to receive direct dial-in details. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q4 and year-end 2024 shareholder update conference call for March 31st, 2025 at 5:00 PM EST. The call will provide updates on all of the company's core businesses.

Shareholders can access the call through:

• Dial-in: 844-695-5519 (US) or 1-412-902-6760 (International)
• Pre-registration link: https://dpregister.com/sreg/10197585/fea81a2627

Investors can submit questions in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.